RecruitingPhase 1NCT07435194

A Clinical Trial in Healthy Participants to Learn How Itraconazole Affects MK-2828 Levels and How MK-2828 Affects Midazolam Levels (MK-2828-007)

A Two-Part Clinical Study to Evaluate the Effects of Multiple Doses of Itraconazole on the Single-Dose Pharmacokinetics of MK-2828 (Part 1) and Multiple Doses of MK-2828 on the Single-Dose PK of Midazolam (Part 2) in Healthy Participants


Sponsor

Merck Sharp & Dohme LLC

Enrollment

28 participants

Start Date

Mar 6, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

The main goals of this study are: * To learn what happens to one dose of MK-2828 in a healthy person's body over time when it is taken with itraconzole * To learn what happens to one dose of midazolam in a healthy person's body over time when it is taken with MK-2828 Researchers want to learn if the levels of MK-2828 in the body are about the same when MK-2828 is taken with itraconazole as when it is taken alone. They also want to know if taking MK-2828 more than once affects how much midazolam is in the body after a single dose.


Eligibility

Min Age: 24 YearsMax Age: 60 Years

Inclusion Criteria1

  • \- Participant is in good health

Exclusion Criteria2

  • History of cancer (malignancy)
  • History of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGMK-2828

Administered orally as capsule

DRUGItraconazole

Administered orally as syrup

DRUGMidazolam

Administered orally as syrup


Locations(1)

Fortea CRU Madison ( Site 0001)

Madison, Wisconsin, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07435194


Related Trials